September seventh, 2023, the University of Birmingham and Acticor Biotech announce the total regulatory approval of LIBERATE clinical study.
In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to guage glenzocimab efficacy in myocardial infarction in a latest clinical trial called LIBERATE. The University has received full regulatory approvals to initiate the study.
This latest clinical trial relies on a long-standing collaboration between Acticor Biotech and the University of Birmingham. The publication in August of a scientific paper from Dr Mark Thomas entitled: “Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy “ (link to the publication) within the Journal of Thrombosis and Haemostasis, reinforced the mode of motion of glenzocimab and its major role as an antithrombotic drug.
The randomized, double-blind Phase 2b LIBERATE study will recruit greater than 200 patients affected by a ST-elevation myocardial infarction (STEMI) and planned for a percutaneous coronary intervention. The study goals to evaluate the protection and the efficacy of glenzocimab 1000 mg versus placebo to scale back the myocardial infarct size at Day 90 post-treatment. The trial might be conducted in two acute care hospitals within the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. Patient recruitment is anticipated to begin by the tip of 2023.
Doctor Mark Thomas, Associate Professor of Cardiology on the University of Birmingham and Honorary Consultant Cardiologist, who designed the trial and led its development, said: “Our recent studies of glenzocimab on the University of Birmingham have just been published – these explain the cellular mechanisms for why it is extremely effective at reducing “blood stickiness”, particularly when combined with existing medications. We’re very happy to receive regulatory approval to launch the LIBERATE clinical trial to analyze whether glenzocimab can reduce the kind of blood clotting that causes heart damage during heart attacks. This exciting collaboration with Acticor has the potential to learn our patients in Birmingham and Sheffield, and internationally.”
Professor Jon Townend, Consultant Cardiologist at University Hospitals Birmingham, Honorary Professor of Cardiology within the Institute of Cardiovascular Sciences on the University of Birmingham, and Chief Investigator of the trial said: “This latest drug looks extremely promising and we’re excited to be nearby of starting recruitment for this vital trial.”
Glenzocimab has already delivered very promising ends in the treatment of acute ischemic stroke and we hope to verify its therapeutics potential in other cardiovascular emergency indications. LIBERATE phase 2b study extends glenzocimab development program to myocardial infarction. We’re delighted to collaborate with all of the teams involved, the University of Birmingham particularly, sponsor of this study, to increase the therapeutic field of glenzocimab.”
Yannick Pletan, Chief Medical Officer, and General Manager of Acticor Biotech